Post on 06-Jun-2018
313
REFERENCES
1. Goldman P. Herbal medicines today and the roots of modern pharmacology.
Annals of Internal Medicine 2001; 135: 594-600.
2. Bodiwala HS, Singh IP. New drug molecules from nature. Express Pharma Pulse
2005; Feb. 3: pp 26.
3. Alschuler L, Benjamin SA, Duke JA. Herbal medicine – what works, what is safe.
Patient Care 1997; 31: 48-103.
4. Kumar V, Parmer NS. Herbs: A Potential source for the development of new
phytochemicals. The Pharma Review 2003; 6th June: 59-62.
5. Bindseil KU, Jakupovic J, Wolf D, Lavayre J, Leboul J, Pyl DVD, Pure
Compound libraries; A new perspective for natural product based drug discovery.
Drug Development Technology 2001; 16(6): 840-847.
6. Patric McGee. Natural products re-emerge. Drug Discovery and Development
2006; 6: 18-26.
7. Peter AGM, De Smet. The role of plant-derived drugs and herbal medicines in
health care. Drugs 1997; 54(6): 801-840.
8. Bent S, Richard KO. Commonly used herbal medicines in the United States: A
Review. American Journal of Medicine 2004; 116: 478-485.
9. Kamboj VP. Herbal Medicine. Current Science 2000; 78(1): 35-39.
10. Patwardhan B, Vaidya ABD, Chorghade M. Ayurveda and natural products drug
discovery. Current Science 2004; 86(6): 789-799.
11. Patwardhan B. Ayurveda-The designer medicine: A review of
ethnopharmacology and bioprosepecting research. Indian Drugs. 2000; 37(5):
213-227.
314
12. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and
development. Journal of Natural Products 1997; 60: 52-60.
13. Harvey AL. Medicines from nature: Are natural product still relevant to drug
discovery? Trends Pharmacological Sciences 1999; 20: 196-198.
14. Guidelines for the assessment of he rbal medicines, document No. WHO/TRM/
91.4 WHO, Geneva 1991.
15. Pal SK, Shukla Y. Herbal Medicine: Current status and the future. Asian Pacific
Journal of Cancer Prevention 2003; 4: 281-288.
16. Jin-Ming K, Ngoh-Khang G, Lian-Sai C, Tet-Fatt C. Recent advances in
traditional plant drugs and orchids. Acta Pharmacologica Sinica 2003; 24(1): 721-
731.
17. Gottlieb S. US relaxes its guidelines on herbal supplements. British Medical
Journal 2000; 320: 207-212.
18. Brevoort P. The booming US botanical market. A new overview. Herbal Gram
1998; 44: 33-44.
19. Robert P Borris. Natural products research: Perspectives from a major
pharmaceutical company. Journal of Ethnopharmacology 1996; 51: 29-38.
20. Chopra RN, Chopra IC, Nayar SL. Glossary of Indian Medicinal Plants.
Publications and information Directorate, CSIR, New Delhi. 1956; pp 241-245
21. 21. Anonymous, The Wealth of India, Raw Materials. Publications and
Information Directorate, CSIR, New Delhi. 1976; 10: pp 161-164.
22. Nadkarni KM. Indian Materia Medica 3rd edition. Popular Pakistan Pvt. Ltd.
Bombay. 1982; 1: pp 1192-1202.
315
23. Chopra RN, Chopra IC, Handa KL, Kapur LD. Chopra’s Indigenous drugs of
India. 2nd Edition, Academic publishers, Calcultta. 1994; pp 421- 424.
24. Kirtikar KR, Basu BD. Indian Medicinal Plants. 3rd reprint, International Book
Publications, Dehradun. 1996; 2: pp 1023-1028.
25. Chatterjee A, Pakrashi SC. The Treatise on Indian Medinal Plants. Publications
and Informations Directorate, CSIR, New Delhi 1997; 3: pp 196-201.
26. Sharma PC, Yelne MB, Dennis TJ. Data Base on Medicinal Plants Used in
Ayurveda. Central Council for Research in Ayurveda and Siddha, New Delhi.
2001; 3: pp 56-75.
27. Kumar DS, Prabhakar YS. On the ethnomedical significance of arjuna tree
Terminalia arjuna (roxb) Wight and Arnot. Journal Ethnopharmacology. 1987;
20(2): 173-190.
28. Dwivedi S, Udupa N. Terminalia arjuna - Pharmacognosy, phytochemistry,
pharmacology and clinical use – A review. Fitoterapia 1989; 60(5): 413-420.
29. Tripathi VK, Singh B, Tripathi RC, Upadhyay RK, Pandey VB. Terminalia
arjuna – its present status. Oriental Journal of Chemistry 1996; 12 (1): 1-16.
30. Rahman Z, Kohli K, Khar KK, Lamba HS, Rathore A, Pah WR. An overview of
Terminalia arjuna: Chemistry and pharmacological profile. Indian Drugs 2004;
41 (11): 641- 649.
31. Nagar A, Gujral VK and Gupta SR. Arjunone – a new flavonone from Terminalia
arjuna – its constituents and synthesis. Planta Medica 1979; 37(2): 183-185.
32. Madhusudanama W, Sastry KNS, Rao VSS, Reddy KK. Isolation of flavan -3-ols
from arjuna (Terminalia arjuna). Leather Science 1980; 27: 199-200.
316
33. Ta-chen, Ma Ying-Tsun, Hsu-Feng-Lin. Tannins from the bark of Terminalia
arjuna. Chinese Pharmaceutical Journal 1996; 48: 25-35.
34. Ramachandra Rao L, Subba Rao GSR. Chemistry of Terminalia species IV.
Chemical examination of Terminalia arjuna – Isolation of arjunolic acid saponin
and (+) leucodelphidinidine. Journal of Indian Chemical Society 1962; 39: 89-92.
35. Nagar A, Gujral VK, Gupta SR. A new flavone from Terminalia arjuna fruits.
Phytochemistry 1979; 18 (7): 1245.
36. Sharma PN, Shoeb A, Kapil RS. Arjunolone a new flavone from stem bark of
Terminlia arjuna. Indian Journal of Chemistry 1982; 21 B(3): 263-264.
37. Anjaneyulu ASR, Ramprasad AV. Chemical examination of the roots of
Terminalia arjuna. The structure of arjunoside III and arjunoside IV – two new
triterpenoid glycosides. Phytochemistry 1982; 21 (8): 2057-2060.
38. Singh B, Pandey VB. Constituents of Terminalia arjuna fruits. Oriental Journal of
Chemistry 1995; 11 (2): 185-186.
39. Chauhas SMS, Mishra MK, Parakas S, Kaushik R. Isolation of phenolics from
leaves of Terminalia arjuna. Journal of Indian Chemial Society 1998; 75(5) : 328-
329.
40. Kandil FE, Nassar MI. A tannin anti – cancer promoter from Terminalia arjuna.
Phytochemistry 1998; 47 (8): 1567-1568.
41. King FE, King TJ, Ross JM. The Chemistry of extractives from hard woods
XVIII. The constituents of arjunolic acid – a triterpene from Terminalia arjuna.
Journal of Chemical Society 1954; 3995-4003.
317
42. Ali E, Hag N, Rah, AKM. Chemical investigation of Terminalia arjuna-I.
Examination of the fruit . Scientific Research 1966; 3 (3): 157-162.
43. Row LR, Murthi PS, Rao GSRS, Sastry CSP, Rao KVJ. Chemical examination of
Terminalia species XII. Isolation and structural determination of arjunic acid – a
new trihydroxy triterpene carboxylic acid from Terminalia arjuna bark. Indian
Journal of Chemistry 1970; 80: 716-718.
44. Murae HT, Tsuyuki T, Takahashi T. The structure of arjungenin – a new saponin
from Terminalia arjuna. Chemical and Pharmaceutical Bulletin 1976; 24: 178.
45. Murae HT, Tsuyu KT, Takahashi T, Sawai M. Arjungenin, arjunglucoside I and
arjunglucoside II - A new triterpene and triterpenoid glycoside from Terminilia
arjuna. Bulletin of Chemical Society of Japan 1979; 49 (11): 3213-3218.
46. Anjaneyulu ASR, Ram Prasad AV. Chemical examination of roots of Terminalia
arjuna (Roxb) Wight & Arnot. Part 1. Characterisation of two new triterpenoid
glycosides. Indian Journal of Chemistry 1982; 21 B (6): 530-533.
47. Anjaneyulu ASR, Ram Prasad AV. Structure of terminic acid - a dihydroxy
triterpene carboxylic acid from Terminalia arjuna. Phytochemistry 1983; 22 (4):
993-998.
48. Ahmed MV, Mullah KB, Norin T, Ulla JK. Terminoic acid – new trihydroxy
triterpene carboxylic acid from the bark of Terminalia arjuna. Indian Journal of
Chemistry 1983; 22(8): 738-740.
49. Bag BG, Subash R, Pramanik K and Maity GC. Arjunolic acid in molecular
recognition: First synthesis and cation biniding studies of a novel arjuna-18-
crown. Supramolecular Chemistry 2005; 17 (4): 297-302.
318
50. Row LR. Chemical examination of Terminalia species XIII. Isolation and
structure determination of arjunetin from Terminalia arjuna. Indian Journal of
Chemistry 1970; 8: 772.
51. Tsuyuki TKO, Hamada Y, Honda T, Takahashi T, Matsuhita K. A new
triterpenoid glycoside from Terminalia arjuna: Arjunoglucoside III. Bulletin of
Chemical Society of Japan 1979; 52 (10): 3127-3128.
52. Tripathi VK, Pandey VB, Udupa KN, Rucker G. Arjunolotin – a triterpene
glycoside from Terminalia arjuna. Phytochemistry 1992; 31 (1): 349-351.
53. Singh B, Singh VP, Pandey VB, Ruker G. A new triterpene glycoside from
Terminalia arjuna. Planta Medica 1995; 61 (6): 576-577.
54. Upadhyay RK, Pandey MB, Jha RN, Singh VP, Pandey VB. Triterpene glycoside
from Terminalia arjuna. Journal of Asian Natural Products Research 2001; 30
(3): 207-212.
55. Chouksey BK, Srivastava SK. New constituents from the roots of Terminalia
arjuna as antifungal agent. Indian Journal of Chemistry 2001; 40B (4): 354-356.
56. Singh DV, Verma RK, Singh SC, Gupta MM. RP-LC determination of oleane
derivatives in Terminalia arjuna. Journal of Pharmaceutical and Biomedical
Analysis 2002; 28 (3 – 4): 447- 452.
57. Singh DV, Verma RK, Gupta MM, Kumar S. Quantitative determination of
oleane derivatives in Terminalia arjuna by high performance thin layer
chromatography. Phytochemical Analysis 2002; 13 (4): 207-210.
58. Ali A, Kaur G, Hamid H, Abdullah T, Ali M, Niwa M, Alam MS. Terminoside A
– a new novel naphthanol glycoside from bark of Terminalia arjuna with anti-
319
oxidant and nitric oxide production in murine macrophages. Journal of Asian
Natural Products Research 2003, 5 (2): 137-142.
59. Ali A, Kaur G, Hayat K, Ali M, Ather M. A novel naphthanol glycoside from
Terminalia arjuna with anti oxidant and nitric oxide inhibitory activities.
Pharmazie 2003; 58 (12): 932-934.
60. Yadav RN, Rathore K. A new cardenolide from the seeds of Terminalia arjuna
(W&A). Journal of Asian Natural Products Research 2000; 2 (2): 97-101.
61. Yadav RN, Rathore K. A new cardenolide from the roots of Terminalia arjuna.
Fitoterapia 2001; 72 (4): 459-461.
62. Ahmed MU, Mullah KB, Saha KC. Hentricontane, arachidic stearate and merisyl
oleate from the fruit of Terminalia arjuna (Combretaceae). Journal of Bangladesh
Academic Sciences 1982; 6: 61-65.
63. Singh N, Kapoor K.K, Singh SP, Shankar K, Sinha JN. Kohli RP. Mechanism of
cardiovascular action of Terminalia arjuna. Planta Medica1982; 45 (2): 102-104.
64. Srivastava RD, Dwivedi S, Srinivasan KK, Chandrasekar KN. Cardiovasular
effects of Terminalia species of plants. Indian Drugs 1992; 29 (4): 144-149.
65. Takahashi S, Tanaka H, Hano Y, Ito K, Nomura T, Shigenobu K. Hypotensive
effects in rats of hydrophilic extract from Terminalia arjuna containing tannin
related compounds. Phytotherapy Research 1997; 11 (6): 424-427.
66. Nammi S, Gudavalli R, Behara S, Babu R, Lodagala DS, Boini KM. Possible
mechanisms of hypotension produced by 70% methanolic extract of Terminalia
arjuna in anesthetized dogs. Biomedcentral Complementry and Alternative
Medicine 2003; 3: 5.
320
67. Dwivedi S, Chansouria JPN, Somani PN, Udupa KN. Influence of certain
indigenous drugs on the prostaglandin E2 like activity in the ischaemic rabbit
aorta. Indian Drugs 1987; 24(8): 378-382.
68. Pathak SR, Singh RH, Udupa KN. A biochemical study on the effect of
Terminalia arjuna in acute myocardial infarction – an experimental study. Probe
1992; 31 (2): 163-168.
69. Tandon S, Rastogi R and Kapoor NK. Protection by Abana - a herbomineral
preparation against myocardial necrosis in rats induced by isoproterenol.
Phytotherapy Research 1996; 10: 263-265.
70. Bhatia J, Bhattacharya SK, Mahajan P, Dwivedi S. Experimental evaluation of the
cardiovascular and cardio protective effects of Terminalia arjuna. Indian Journal
of Pharmacology 1999; 31 (1): 57.
71. Radhakrishnan R, Wardsworth RM, Gray AI. Terminalia arjuna – an Ayurvedic
cardiotonic, increases contractile force of rat isolated arteria. Phytotherapy
Research 1995; 7 (3): 266-268.
72. Karam Setty M, Ferrie TJ, Kane KA, Gray AI. Effect of an aqueous extract of
Terminalia arjuna on isolated rat atria and thoracic aorta. Phytotheapy Research
1995; 9 (8): 575-578.
73. Bhatia J, Battacharya SK, Mahajan P, Dwivedi.S. Effect of Terminalia arjuna on
coronary flow – an experimental study. Indian Journal of Pharmacology 1998; 30
(2); 118-119.
321
74. Gauthaman K, Maulik M, Manchanda SC, Maulik SK. Antioxidant effect of
chronic treatment with Terminalia arjuna bark on ischaemic reperfusion injury in
rat heart. Indian Journal of Pharmacology 1999; 31(1): 78.
75. Gauthaman K, Maulik M. Kumari R, Manichandra SC, Dinda AK, Maulik SK.
Effect of chronic treatment with bark of Terminalia arjuna: A study on the
isolated ischaemic reperfused rat heart. Journal of Ethnopharmacology 2001; 75
(2-3): 197-201.
76. Karthikeyan K, Sarabhai BR, Gauthaman K. Sathish KS, Niranjali Devaraj S.
Cardio protective effect of the methanolic extract of Terminalia arjuna bark in an
in-vivo model on myocardial ischaemic reperfusion injury. Life Sciences 2003; 73
(21): 2727-2739.
77. Gauthaman K, Banerjee SK, Dinda AK, Ghosh CC, Maulik SK, Terminalia
arjuna (Roxb.) protects rabbit heart against ischaemic reperfusion injury: role of
antioxidant enzymes and heart shock proteins. Journal of Ethnopharmacology
2005; 96 (3): 403-409.
78. Tripathi VK, Singh B, Jha RN, Pandey, Udupa KN. Studies on Arjuna in
coronery heart disease. Journal of Research in Ayurveda and Siddha 2000; 21(1-
2): 37-40.
79. Dwivedi S, Aggarwal A, Agarwal MP, Rajpal S. Role of Terminalia arjuna in
ischaemic mitral regurgitation. International Journal of Cardiology 2005; 100(3):
507-508.
80. Colobawalla HM. An evaluation of the cardiotonic and other properties of
Terminalia arjuna. Indian Heart Journal 1951; 3 (3): 205-230.
322
81. Antani JA, Gandhi S and Antani NJ. Terminalia arjuna in congestive heart
failure. Journal of the Association of Physicians of India. 1991; 39: 801.
82. Bharani A, Ganguli A, Bhargava KD. Salutary effect of Terminalia arjuna in
patients with severe refractory heart failure. International Journal of Cardiology
1995; 49 (3): 191-199.
83. Dwivedi S, Chansouria JPN, Somani PN, Udupa KN. Effect of Terminalia
arjuna in ischaemic heart diseases. Alternative Medicine 1989; 3(2): 115-122.
84. Jain V, Pooma A, Agarwal RP, Panwar RB, Kochar DK, Misra RN. Effect of
Terminalia arjuna in patients of angina pectoris. (A clinical trial). Indian Medical
Gazette 1992; 126(2): 56-59.
85. Dwivedi S, Agarwal MP. Antianginal and cardioprotection effects of Terminalia
arjuna – an indigenous drug in coronary artery disease. Journal of Association of
Physicians of India 1994; 42: 287-289.
86. Dwivedi S, Jauhari R. Beneficial effects of Terminalia arjuna in coronary artery
disease. Indian Heart Journal 1997; 49(5): 507-510.
87. Kumar PV, Adikari P, Periera P, Bhat P. Safety and efficacy of Hartone in stable
angina pectoris – an open comparative trial. Journal of Association of Physicians
of India 1999; 47: 685-689.
88. Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG. Efficacy of Terminalia
arjuna in chronic stable angina: a double blind, placebo controlled, cross over
study comparing Terminalia arjuna with isosorbide mononitrate. Indian Heart
Journal 2002; 54(4): 441.
323
89. Tiwari AK, Gode JD, Dubey GP. A comparative study between Terminalia
arjuna and cholestyramine effect on serum lipids and lipoproteins in
hypercholesterolomic rabbits. Indian Drugs 1989; 26(12): 664-667.
90. Tiwari AK, Gode JD, Dubey GP. Effect of Terminalia arjuna on lipid profiles of
rabbit fed hypercholesterolemic diet. Journal of Crude Drug Research 1990;
28(1): 43-47.
91. Pathak SR, Upathyay L, Singh RH, Dubey GP, Udupa KN. Effect of Terminalia
arjuna (W&A) on autocoidal and lipid profiles of rabbits. Indian Drugs 1990;
27(4): 225-227.
92. Khanna AK, Chander R, Kapoor NK. Terminalia arjuna: An ayurvedic cardio
tonic regulates lipid metabolism in hyperlipidemic rats. Phytotherapy Research
1996; 10(8): 663-665.
93. Shaila HP, Udupa SL, Udupa AL, Nair NS. Effect of Terminalia arjuna on
experimental hyperlipidemia in rabbits. International Journal of Pharmacognosy
1997; 35(2): 126-129.
94. Ram A, Lauria P, Gupta R, Kumar P, Sharma VN. Hypocholesterolaemic effects
of Terminalia arjuna tree bark. Journal of Ethonopharmacology 1997; 55(3): 165-
169.
95. Shaila HP, Udupa SL, Udupa AL. Hypolipidemic effect of Terminalia arjuna in
cholesterol fed rabbits. Fitoterapia 1997; 68(5): 405-409.
96. Shaila HP, Udupa SL, Udupa AL. Hypolipidemic activity of three indigenous
drugs in experimentally induced atherosclerosis. International Journal of
Cardiology 1998; 67(2): 119-124.
324
97. Shaila HP, Udupa SL. Udupa AL. Hypocholesterolemic activity in rats of
different fractions from Terminalia arjuna. Pharmacy and Pharmacology
Communication 2000; 6: 327-330.
98. Chatterjee S. Terminalia arjuna improves endothelial vasodilator function in
cholesterol fed rabbits. Indian Drugs 2000; 37(9): 433-436.
99. Dubewar VM. Effect of Arjuna, vacha and mrugashrunga Bhasma in
atherosclerosis (Dhamani Practichaya) animal experiments. Phytomedicine 2000;
7 (Suplement-II): 116.
100. Gupta R, Singhal S, Goyle A, Sharma VN. Antioxidant and
hypercholesterolemic effects of Terminalia arjuna tree bark powder: a
randomized placebo controlled trial. Journal of Association of Physicians
India 2001; 49: 231-235.
101. Jain AK, Shimoi K, Nakamura V, Tomita I, Kada T. Prelimanary study on the
desmutagenic and antimutagenic effect of some natural products. Current
Science 1987; 56(24): 1266-1269.
102. Pettit GR, Hoard MS, Doubek DL, Schmidt JM, Pettit RK, Tackett LP, Chapuis
JS. Antineoplastic agents 338: The cancer cell growth inhibitory constituents of
Terminalia arjuna (Combretaceae). Journal of Ethnopharmacology 1996; 53(2):
57-63.
103. Kaur S, Grover IS, Kumar S. Antimutagenic potential of ellagic acid isolated
from Terminalia arjuna. Indian Journal of Experimental Biology 1997; 35(5):
478-482.
325
104. Scassellati-Sforzolini G, Villarini LM, Moretti LM, Marcarelli LM, Paquini R,
Fatigoni C, Kaur LC, Kumar S, Grover IS. Antigeonotoxic properties of
Terminalia arjuna bark extracts. Journal of Environmental Pathology,
Toxicology and Oncology 1999; 18(2): 119-125.
105. Nagpal A, Meena LS, Kaur S, Grover IS, Wadhwa R, Kaul SC. Growth
Suppression of human transformed cells by treatment with bark extracts from a
medicinal plant Terminalia arjuna. In vitro Cellular and Developmental
Biology - Animal 2000; 36(8): 544-547.
106. Kaur SJ, Grover IS, Kumar S. Modulatory effects of tannin fraction isolated
from Terminalia arjuna on the genotoxicity of mutagens in Salmonella
typhimurium. Food and Chemical Toxicology 2000; 38(12): 1113-1119.
107. Pasquini R, Scassellati- Sforzolini G, Vilarini M, Moretti M, Marcarelli M,
Fatigoni C, Kaur S; Kumar S, Groover IS. In-vitro protective effects of
Terminalia arjuna bark extracts against 4- nitroquinoline-N-oxide genotoxicity.
Journal of Environmental Pathology, Toxicology and Oncolology 2002; 21(1):
33-44.
108. Kaur K, Arora S, Kumar S, Nagpal A. Antimutagenic activities of actone and
methanol fractions of Terminalia arjuna. Food and Chemical Toxicology 2002;
40(10): 1475-1482.
109. Kuo PL, Hsu YL, Lin TC, Chang JK, Lin CC. Introduction of cell cycle arrest
and apoptosis in human non-small cell a lung cancer. A 549 cells by casuarinin
from the bark of Terminalia arjuna Linn. Anticancer Drugs 2005; 16(4): 409-
415.
326
110. Kao PL, Hsu YL, Lin TC, Lin LT, Chang JK, Lin CC. Casuarinin from the bark
of Terminalia arjuna induces apoptosis and cell cycle arrest in human breast
adenocarcinoma MCF-7 cells. Planta Medica 2005; 71(3): 237-243.
111. Sivaloganathan S, Ilayaraja M, Balasubramanian MP. Efficacy of Terminalia
arjuna (Roxb.) on N-nitrosodiethylamine induced hepatocellular carcinoma in
rats. Indian Journal of Experimental Biology 2005; 43(3): 264-267.
112. Sama SK, Krishnamurthy L, Ramachandran K, Lal L. Efficacy of an indigenous
compound preparation (Liv 52) in acute viral hepatitis – a double blind study.
Indian Journal of Medical Research 1976; 64: 738-742.
113. Subbarao VV, Guptha ML. Changes is serum transaminase due to hepatotoxicity
and the role of an indigenous hepototonic Liv 52. Probe 1978; 17(2): 175-178.
114. Sethi JP, Sharma M. Clinical management of severe acute hepatic failure with
special reference to Liv 52 in therapy. Probe 1978; 17(2): 155-158.
115. Mandal JN, Roy BK. Studies with Liv 52 in the treatment of infective hepatitis,
chronic active hepatitis and cirrhosis of the liver. Probe 1983; 22(4): 217-242.
116. Aggarwal NW, Prasad B, Sharma M, Sharma B. Role of Liv 52 in Indian
childhood cirrhosis with special reference to its effect on alpha-1-antitrypsin
levels. Probe 1983; 22(4): 243-250.
117. Sandhir R, Gill KD. Hepatoprotective effects of Liv 52 on ethanol induced liver
damage in rats. Indian Journal of Experimental Biology 1999; 37(8): 672-766.
118. Gote W, Kusumoto IT, Kadota S, Namba T, Kurukawa M, Shiraki K.
Suppression of Hepatitis B virus surface antigen secretion by traditional plant
medicines. Phytotherapy Research 1996; 10(6): 504-507.
327
119. Kurokawa M, Ochiai M, Nagasaka K, Neki M, Xu-Xx, Kadota S, Matsumoto T,
Namba T, Shiraki K. Anti-viral traditional medicines against herpes simplex
virus (HSV-1), polio virus and measles virus in-vitro and their therapatic
efficacies for HSV-1 infection in mice. Antiviral Research 1993; 22(2/3): 175-
188.
120. Kurokawa M, Nagasaka K, Hirabayashi T, Oyma SI, Sato H, Kageyama T,
Kadota S, Ohyama H, Hozumi T, Namba T, Schiraki K. Efficacy of traditional
herbal medicines in combination with acyclovir against herpes simplex virus
Type 1 infection in vitro and in vitro. Antiviral Research 1995; 27(1/2): 19-37.
121. Kusumo IT, Nakabayashi T, Kida H, Miyashiro H, Hattori M, Namba T,
Shimutohno K. Screening of various plant extracts used in Ayurvedic medicine
for inhibitory effects on human immunodeficiency virus type 1 (HIV-protease).
Phytotherapy Research 1995; 9: 180-184.
122. Cheng HY, Lin CC, Lin TC. Antiherpes simplex virus type 2 activity of
casuarinin from the bark of Terminalia arjuna Linn. Antiviral Research 2003;
55(3): 447-455.
123. Munasinghe JTC, Seneviratne CK, Thabrew M, Abeysekara AM. Anti-radical
and antilipoperoxidative effects of some plants extracts used by the Srilankan
traditional medicinal practioners for cardio protection. Phytotherapy Research
2001; 15; 519-523.
124. Chen CH, Lin TZ, Kuo TC, Lu FJ, Chen YC, Chang - Chien YW, Lin CC.
Casuarinin protects MDCK cells from hydrogen peroxide induced oxidative
stress and DNA oxidative damage. Planta Medica 2004; 70(11): 1022-1026.
328
125. Chander R, Singh K, Khanna AK, Kaul SM, Puri A, Saxena R, Bhatia G, Rizvi
F, Rastogi AK. Andidyslipidemic and antioxidant activities of different fractions
of Terminalia arjuna stem bark. Indian Journal of Clinical Biochemistry 2004;
19(2): 141-148.
126. Pawar RS, Bhutani KK. Effect of oleanane triterpenoids from Terminalia arjuna
- a cardioprotective drug on the process of respiratory oxyburst. Phytomedicine
2005; 12(5): 391-393.
127. Sivalokanathan S, Ilayaraja M, Balasubramanian MP. Antioxidant activity of
Terminalia arjuna bark extract on N - nitrosodiethylamine induced
hepatocellular carcinoma in rats. Molecular and Cellular Biochemistry 2006;
28(12): 87-93.
128. Prakash AO, Mathur R. Screening of Indian plants for antifertility. Indian
Journal of Experimental Biology 1976; 623-626.
129. Yadav BL, Mathur R, Gupta RB. Antitertility activity of Terminalia arjuna
(W&A) in female albino rats. Probe 1980; 19(3): 196-198.
130. Gupta DN, Keshri G, Laxmi V and Kapil RS. Post coital contraceptive efficacy
of Terminalia arjuna in albino rats. Fitoterapia 1989; 60(3): 275-276.
131. Lal B, Udupa KN. A preliminary study of antifertility effect of an indegeneous
drug arjuna. Journal of Research in Ayurveda and Siddha 1993; 14(3-4): 165-
169.
132. Prasad MVV, Anbalagan N, Patra A, Veluchamy G, Balakrishna K. Antiallergic
and Anti-asthmatic activities of methanolic extract of Terminalia arjuna and
arjunolic acid. Natural Product Sciences 2004; 10(5): 240-243.
329
133. Manonmani G, Anbarasi K, Balakrishna K, Veluchamy G, Shyamaladevi CS.
Effect of Terminalia arjuna on the antioxidant defense system in alloxan
induced diabetes in rats. Biomedicine 2002; 22(3&4): 52-61.
134. Rane MM, Mengi SA. Comparative effect of oral administration and topical
application of alcohol extract of Terminalia arjuna bark on incision and excision
wounds in rats. Fitoterapia 2003; 74 (6): 553-558.
135. Chaturvedi PN. A study on the effect of an indigenous drug arjuna (Terminalia
arjuna W & A). On arterial thrombosis and ischaemic heart disease. M.D
Thesis (Ayurveda), Varanasi. 1967.
136. Chatterjee S. Effect of Terminalia arjuna on abnormal platelet reactivity in
hypercholesterolaemic rabbits. Indian Drugs 2000; 37 (3): 135-138.
137. Sathyanarayana S, Srinivas N, Subramanya Kumar NV. Studies on the effect of
70% methanolic extract of Terminalia arjuna on the haematology of dog. Indian
Drugs 1999; 36 (3): 198-199.
138. Bharani A, Ahirwar LK, Jain N. Terminalia arjuna reverses impaired endothelial
function in chronic smokers. Indian Heart Journal 2004; 56(2): 123-128.
139. Ray PG, Majumdar SK, Antimicrobial activity of some Indian plants. Economic
Botany 1976; 30: 317-330.
140. Ahmed I, Mehmoz, Mohammad F. Screening of some Indian medicin plants for
their anti-microbial properties. Journal of Ethnopharamacology 1998; 62(2):
183-193.
330
141. Perumal Samy R, Ignacimuthu S, Sen A. Screening of 34 Indian medical plants
for antibacterial properties. Journal of Ethnopharamacology 1988; 62(2): 173-
181.
142. Rani P, Khullar N. Antimicrobial evaluation of some medicinal plants for their
anti enteric potential against multi drug resistant Salmonella typhi. Phytotherapy
Research 2004; 18(8): 670-673.
143. Lalman C, Misra A. Fungistatic properties of some higher plants. National
Academy of Scientific Letters 1980; 3(1): 19-20.
144. Mehmood Z, Ahmed I, Mohammed F, Ahmad S. Indian medicinal plants. A
potential source for anti candidal drugs. Pharmaceutical Biology 1999; 27(3):
237-242.
145. Thapliyal M, Ghosh M, Bennet SSSR. Screening of 6 medicinal plants for their
antifungal protein activity. Asian Journal of Microbiology 2000; 2(3-4); 215-
218.
146. Diallo B, Vanhaelen M, Vanhaelen-Fastre R, Konoshima T, Kozuka M, Tokuda
H. Studies on inhibitors of skin-tumor promotion. Inhibitory effects of
triterpenes Cochlospermum tinctorium on Epstein-Barr virus activation. Journal
of Natural Products 1989; 52: 879-881.
147. Sumitra M, Manikandan P, Ashok Kumar D, Arutselvan N, Balakrishna K,
Murali Manokar B, Puvanakrishnan R. Experimental myocardial necrosis in rats:
Role of arjunolic acid on platelet aggregation, coagulation and antioxidant status.
Molecular and Cellular Biochemistry 2001; 224(1-2); 135-142.
331
148. Bhakuni RS, Shukla YN, Tripathi AK, Prajapati V, Kumar S. Insect growth
inhibitor activity of arjunolic acid isolated from Cornus capitata. Phytotherapy
Research 2002; 16: S68-S70.
149. Djoukeng JD, Abou-Mansour E, Tabacchi R, Tapongjou AL, Bouda H, Lontsi
D. Antibacterial triterpenes from Syzygium guineense (Myrtaceae). Journal of
Ethnopharmacology 2005; 101: 283-286.
150. Facundo VA, Ries KA, Medeiros CM, Militao JSLT, Miranda ALP, Epifanio
RA, Carvalho MP, Andrade AT, Pinto AC, Rezende CM. Arjunolic acid in the
ethanolic extract of Combretum leprosum root and its uses as a potential multi-
functional phytomedicine and drug for neurodegenerative disorders : Anti-
inflammatory and anticholinesterasic activities. Journal of Brazilian Chemical
Society 2005; 16(6B): 1309-1312.
151. Diallo B, Vanhaelen M, Vanhaelen-Fastre R, Konoshima T, Takasaki M,
Tokuda H. In-vivo inhibitory effects of arjunolic acid derivatives on two stage
carcinogenesis in mouse skin. Phytotherapy Research 1995; 9: 444-447.
152. The Ayurvedic Pharmacopoeia of India, Part 1, Vol. II, I Edition. Government
of India, Ministry of Health and Family Welfare, New Delhi. 1999. pp 191.
153. Kokate CK. Practical Pharmacognosy. 2nd Edition. Vallabh Prakashan, New
Delhi. 1990; pp 119-121.
154. Harborn JB. Phytochemical Methods: A guide to modern techniques of plant
analysis. Chapman and Hall Publications, London. 1988; pp 293.
155. Mendham J, Denney RC, Barnes JD, Thomas MJK. In: Vogel’s Quantitative
Chemical Analysis. 5th Reprint, Pearson Education, Delhi. 2004; 446-447.
332
156. Furniss BS, Hannaford AJ, Smith PWG, Tatchell AS. In: Vogel’s text book of
practical organic chemistry. Addison – Wesley Longman Ltd. 5th Edition, 1989.
pp 430 – 433.
157. Lee TH, Chiou JL, Lee CK, Kuo YH. Seperation and determination of chemical
constituents in the roots of Rhus javanica L var. roxburghiana. Journal of
Chinese Chemical Society 2005; 52: 833-841.
158. Shirane N, Hashimoto Y, Ueda K, Takenaka H, Katoh K. Ring-A cleavage of 3-
oxo-olean-12-ene-28-oic acid by the fungus Chaetomium longirostre.
Phytochemistry 1996; 43(1): 99-104.
159. Furuya T, Orihara Y, Hayashi C, Triterpenoids from Eucalyptus perriniana
cultured cells. Phytochemistry 1987; 26 (3): 715-719.
160. Shao Y, Zhou BN, Lin LZ, Cordell GA. Triterpenoids saponins from Aster
yunnanesis. Phytochemistry 1995; 38 (6): 1487-1492.
161. Tori K, Seo S, Shimaka A, Tomita Y. Carbon-13 NMR spectra of olean-12-enes.
Full signal assignments including couplings. Tetrahedran Letters. 1974; 4227-
4230.
162. Woo WS, Choi JS, Seligmann O, Wagner H. Sterol and triterpenoid glycosides
from the roots of Patrinia scabiosaefolia. Phytochemistry 1983; 22(4): 1045-
1047.
163. Ikuta A, Itokawa H. Triterpenoids of Paeonia japonica callus tissue.
Phytochemistry 1988; 27(9): 2813-2815.
164. Viana FA, Braz-Filho R, Pouliquen YBM, Neto MA, Santiago GMP, Rodrigues-
Filho E. Triterpenoid saponins from stem bark of Pentaclethra macroloba.
Journal of Brazilian Chemical Society 2004; 15(4): 595-602.
165. Srivastava SK, Jain DC. Triterpenoid saponins from plants of Araliaceae
Phytochemistry 1989; 28 (2): 644-647.
333
166. Wen X, Sun H, Liu J, Wu G, Zhang L, Wu X, Ni P. Pentacyclic triterpenes. Part
1. The first examples of naturally occurring pentacyclic triterpenes as a new
class of inhibitors of glygogen phyosphorylases. Bio-organic and Medicinal
chemistry Letters. 2005; 15: 4944-4948.
167. Bilia AR, Mendez J, Morelli I. Phytochemical investigations of Licania genus.
Flavonoids and triterpenoids from Licamia Carii. Pharmacetuica Acta Helvetiae
1996; 71: 191-197.
168. Taniguchi S, Imayoshi Y, Kobayashi E, Takamatsu Y, Ito H, Hatano T,
Sakagami H, Tokuda H, Nishino H, Sugita D, Shimura S, Yoshida T. Production
of bioactive triterpenes by Eriobotrya japonica calli. Phytochemistry 2002; 59:
315-323.
169. Ding Y, Kinjo J, Yang CR, Nohara T. Triterpenoids from Mucuna
birdwoodiana. Phytochemistry 1991; 30: 3703-3705.
170. Candy HA, Mc Garry EJ, Pegel KH. Constituents of Syzygium cordatum.
Phytochemistry 1968; 7: 889-890.
171. Lalith Jayasinghe G, Wannigama P, Macleod JK. Triterpenoids from Anamirta
coculus. Phytochemistry 1993; 34 (4): 1111-1116.
172. Ecobichon DJ. The basis of toxicology Testing. CRC press, New York. 1997; pp
43-86.
173. Luigi Tavazzi. Clinical epidemiology of acute myocardial infarction. American
Heart Journal 1999; 138: S48-S54.
174. Murray CJ, Lopez AD. The global burden of disease: A comprehensive
assessment of mortality and disability from disease, injuries and risk factors in
1990 and projected to 2020. Cambridege, Mass: Harvard University. 1996; pp 1-
100.
334
175. Hunin K MG, Goldman L, Tosteson AV. The recent decline in mortality from
coronary heart disease 1980-1990. Journal of American Medical Associan 1997;
277: 535-542.
176. Murray CJL, Lopez A. Mortality by cause for eight regions of the world; global
burden of disease study. Lancet 1997; 349: 1269-1276.
177. Leeder S, Raymond S, Greenberg H, Liu H, Esson K. A race against Time: The
challenge of cardiovascular disease in developing countries. New York, NY:
Trustees of Columbia University 2004; pp 5-25.
178. Gaziano TA. Cardiovascular disease in the developing world and its cost
effective management. Circulation 2005; 112:3547-3553.
179. Reddy KS. CVS disease in India. World Health statistics 1993; 46: 101-107.
180. Koren G, Weiss AT, Hasin Y. Prevention of myocardial damage in acute
myocardial ischaemia by early treatment with intravenous streptokinase.
New England Journal of Medicine. 1985; 313: 1384-1389.
181. Gluseppe H and Isabella T. Reperfusion injury: Experimental evidence and
clinical implications. American Heart Journal 1999; 138: S69-S75.
182. Park JL, Lucchesi BR. Mechanism of myocardial reperfusion injury. Annals of
Thorasic surgery 1999; 68: 1905-1912.
183. Hearse DJ. Myocardial protection during ischaemic and reperfusion. Molecular
and Cellular Biochemistry 1998; 186: 177-184.
184. Vogel HG. Isolated heart according to Lagendorff. In: Drug Discovery and
Evaluation, 2nd Edition, Springer Verlag Publications, Berlin 2002. pp 183.
185. Borchgrevink PC, Schie R, Bergan AS, Bakoy OE, Jynge P. Magnesium and
reperfusion of ischaemic rat heart as assessed by 31P NMR. American Journal of
Physiology 1989; 256; 11195-11204.
335
186. Okhawa H, Ohishi N, Yagi K. Assay of lipid peroxides in animal tissue by
thiobarbituric acid reaction. Analytical Biochemistry 1979; 95: 351-358.
187. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic
indices of lipid peroxidation and peroxidative tissue injury. Free Radicals in
Biology and Medicine 1990; 9: 515-540.
188. Ellman GL. Tissue sulphydryl groups. Archives of Biochemistry and Biophysics
1959; 82: 70-77.
189. McCord JM, Fridovich I. Superoxide dismutase and enzymic function based
approaches. Current Topics in Cell Regulations 1969; 26: 383-394.
190. Kakkar P, Das B, Vishwanathan PN. A modified spectrophotometric assay of
super oxide dismutase. Indian Journal of Biochemistry and Biophysics 1984; 21:
130-132.
191. Aebi H. Catalase In: Methods of Enzymatic Analysis. Edited by Bergmeyer HU.
Verlag Chemic Academic press Inc. 1974; 2: pp 673-685.
192. Sharma GP, Das PK, Single PK. Arteriovenous difference in lactate levels in
myocardial ishaemia and reperfusion. Candadian Journal of Physiology and
Pharmacology 1978; 56: 1059-1063.
193. Implementation of global strategy for health for all by 2000. 2nd evaluation. 8th
report on the world health situation. Vol. 1. Global review, WHO, Geneva, 1993.
pp 113.
194. Zafar R, Mujahid Ali S. Anti-hepatotoxic effects of root and callus extracts of
Cichorium intybus L. Journal of Ethnopharmacology 1988; 63: 227-231.
195. Reitman S, Frankel S. Determination of serum glutamate oxaloacetate and
glutamic pyruvic acid transaminases. American Journal of Clinical Pathology
1957: 28: 56-66.
336
196. Kind PNR, King AJ. Estimation of plasma phosphatase by determination of
hydrolysed phenol with aminopyrines. Journal of Clinical Pathology 1954; 7:
322-326.
197. Malloy HT, Evelyn KA. The determination of bilirubin with the photoelectrtic
colorimeter. Journal of Biologial Chemistry 1937; 119: 481-485.
198. Lowry OH, Rosebrough NJ, Farr AL, Radall RJ. Protein measurement with
Folin-Phenol reagents. Journal of Biochemistry 1951; 193: 265-275.
199. Plaa GL, Charbonnean M. Detection and evaluation of chemically induced liver.
In: Priniciples and Methods of Toxicology. Edited by Wallace Hayes A. 4th
Edition, Taylor and Francis. 2001; pp 1175-1177.
200. Winter CA, Risley, EA, Nuss GW. Carrageenan-induced edema in hind paw of
the rat as an assay for anti-inflammatory drugs. Proceeding of a Society for
Experimental Biology and Medicine 1962; 111: 544-547.
201. Irshad M, Chandhuri PS. Oxidant – antioxidant system: Role and significance in
human body. Indian Journal of Experimental Biology 2002; 40: 1233-1239.
202. Ajitha M, Rajnarayana K. Role of oxygen free radicals in human disease. Indian
Drugs 2001; 38(11): 545-554.
203. Nadendla RR. Role of antioxidants in human diseases an overview. Pharmatimes
2002; 34: 13-18.
204. Halliwell B, Gutteridge JM. Free Radicals in Biology and Medicine. Clarendon
Press, Oxford. 1989; pp 23.
205. Halliwell B. Free radicals, antioxidants and human disease: Curiosity, cause or
consequence. Lancet 1994; 67: 85-91.
206. Kehrer JP. Free radicals as mediators of tissue injury and disease. CRC Critical
Reivews in Toxicology. 1993; 23: 21-48.
337
207. Abdalla AE, Roozen JP. Effect of plant extracts on the oxidative stability of
sunflower oil and emulsion. Food Chemistry 1999; 64: 323-329.
208. Sanchez-Moreno C. Methods used to evaluate the free radical scavenging
activity in foods and biological systems. Food Sciences Technology
Internalational. 2002; 8(3): 121-137.
209. Blois MS. Antioxidant determinations by the use of stable free radical. Nature
1958; 181: 1199-1200.
210. Molyneux P. The use of stable free radical diphenyl pricyl hydrazyl (DPPH) for
estimating antioxidant activity. Songklanakarin Journal of Science and
Technology 2004; 26(2): 211-219.
211. Sanchez-Moreno C, Larrauri JA, Saura-Calixto F. A procedure to measure the
antiradical efficacy of polyphenols. Journal of the Science of Food and
Agriculture. 1998; 76: 270-276.
212. Sanchez-Moreno C, Larrauri JA, Saura-Calixto F. Free radical scavenging
capacity of selected red rose and white wines. Journal of the Science of Food and
Agriculture. 1999; 79: 1301-1304.
213. Alderton WK, Cooper CE, Knowles RG. Nitric oxide syntheses: Structure,
function and inhibition. Biochemistry Journal. 2001; 357: 593-615.
214. Patel RP. McAndrew J, Sellak H, White CR, Jo H, Freeman BA. Biological
aspects of reactive nitrogen species. Biochemica et Biophysica Acta 1999; 1411:
385-400.
215. Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer Letters
2005; 226: 1-15.
216. Chen B, Deen WM. Analysis of the effects of cell spacing and liquid depth on
nitric oxide and its oxidation products in cell cultures. Chemical Reasearch and
Toxicology 2001; 14: 135-147.
338
217. Garrat DC. The quantitative analysis of drugs. Vol. 3. Chapman and Hall, Japan.
1964; pp 456-458.
218. Marcocci PL, Scakaki A, Albert GM. Antioxidant action of Gingo biloba
extracts EGP 761. Methods in Enzymology 1994; 234: 462-475.
219. Koster R, Anderson M, De Beer J. Acetic acid for analgesic screening.
Federation Proceedings 1959: 18: 412-417.
220. Luttinger D. Determination of antinociceptive activity of drugs in mice using
different water temperatures in a tail-immersion test. Journal of Pharmacological
Methods 1985; 13: 351-357.
221. Janssen PAJ, Niemegeers CJE, Dony JGH. The inhibitory effect of fentanyl and
other morphine like analgesics on the warm water induced tail withdrawal reflex
in rats. Arzneimittel – Forsch 1963; 13: 502-507.
222. Hearse DJ and Satherland FJ. Experimental models for the study of
cardiovascular function and disease. Pharmacological Research 2000; 41(6);
613-627.
223. Draper HH, Squires EJH, Mahmood JWU, Agarwal S, Hadley M. A comparative
evaluation of thiobarbituric acid methods for the determination of
malondialdehyde in biological materials. Free Radicals in Biology and Medicine
1993; 15: 353-363.
224. Maulik N, Watanabe M, Engelman DT, Engelman RM, Kagan VE, Kisin E,
Tyrin V, Cordis GA, Das DK. Myocardial adaption to ischemia by oxidative
stress induced by endotoxin. American Journal of Physiology 1995; 38: C907-
C916.
225. Ambrosio G, Tritto I. Reperfusion injury. Experimental evidence and clinical
implications. American Heart Journal 1999; 138: S69-S75.
339
226. Hearse DJ. Ischaemia, reperfusion and the determinants of tissue injury.
Cardiovascular Drugs Therapy 1991; 4: 767-776.
227. Kloner RA, Does reperfusion injury exist in humans? Journal of American
College of Cardiology 1993; 21: 537-545.
228. Peuhkurinen KJ. Ischaemic heart disease at the cellular level. Journal of
International Society for Bioelectromagnetism 2000; 2(1): 1-9.
229. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in
reperfused heart using electron spin resonance spectroscopy. Circulation
Research 1987; 61: 1757-1760.
230. Bolli R, Jeroudi MO, Patel BS, Direct evidence that oxygen derived free radicals
contribute to post ischemic myocardial dysfunction in the intact dog.
Proceedings of National Academy of Sciences USA 1989; 86: 4695-4699.
231. Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR.
Reduction of the extent of ischemic myocardial injury by neutrophil depletion in
the dog. Circulation 1983; 67: 1016-1023.
232. Gross GJ, Kersten JR, Wartier DC, Mechanisms of post ischemic contractile
dysfunction. Annals of Thorasic Surgery 1999; 68: 1898-1904.
233. Carden DL, Granger DN, Pathophysiology of ischaemic reperfusion injury.
Journal of Pathology 2000; 190: 255-266.
234. Rao V, Ivanov J, Weisel RD. Lactate release during reperfusion predicts low
cardiac output syndrome after coronary by pass surgery. Annals of Thorasic
Surgery 2001; 71: 1925-1930.
235. Merante F, Mickle DA, Weisel RD, Myocardial aerobic metabolism is impaired
in a cell culture model of cyanotic heart disease. American Journal of Physiology
1998; 275: H1673-H1681.
340
236. Jolly SR, Kane WJ, Bailie MB, Abrams GD and Lucchesi BR. Canine
myocardial reperfusion injury. Its reduction by the combined administration of
superoxide dismutase and catalase. Circulation Research 1984; 54: 277-285.
237. Das DK, Engelman RM, Rouson JA, Breyer RH, Otani H, Lemeshow S.
Pathophysiology of superoxide radical as potential mediator of reperfusion
injury in pig heart. Basic Research in Cardiology 1986; 81: 155-166.
238. Ambrosio G, Becker LC, Hutchins GM, Weisman HF, Weisfeldt ML. Reduction
in experimental infarct size by recombinant human superoxide dismulatase:
Insights into the pathophysiology of reperfusion injury. Circulation 1986; 74:
1424-1433.
239. Omar BA, Gad NM, Jordan MC, Striplin SP, Russel WJ, Downey JM, Mc Cord
JM. Cardioprotection by Cu, Zn-Superoxide dismutase is lost at high doses in the
reoxygenated heart. Free Radical Biology and Medicine 1990; 9: 465-471.
240. Przyklen KK, Kloner RA, “Reperfusion injury” by oxygen derived free radicals?
Effect of superoxide dismutase plus catalase, given at the time of reperfusion, on
myocardial infarct size, contractile function, coronary microvasulature and
regional myocardial blood flow. Circulation Research 1989; 64: 86-96.
241. Przyklen K K, Kloner RA, Oxygen radical scavenging agents as adjuvant
therapy with tissue plasminogen activator in a canine model of coronary
thrombolysis. Cardiovascular Research 1993; 27: 925-935.
242. Flaherty JT, Pitt B, Gruber JW, Heuser RR, Rothbaum DA, Burwell LR, George
BS, Kereiakes DJ, Deitchman D, Gustafson N. Recombinant human superoxide
dismutase (h-SOD) fails to improve recovery of ventricular fraction in patients
undergoing coronary angioplasty for acute myocardial infarction. Circulation
1994; 89: 1982-1991.
341
243. Steare SE and Yellon DM. The potential for endogenous myocardial antioxidant
to protect the myocardium against ischaemic reperfusion injury; refreshing the
parts exogenous antioxidants can not reach. Journal of Molecular and Cellular
Cardiology 1995; 27: 65-74.
244. Sathyanarayana T. Biochemistry, 2nd Edition, Books and Allied (P) Ltd.,
Kolkatta, 2002. pp 244.
245. Blasutein A, Deneke SM, Stolz RI, Baxter D, Healey N, Fanburg BL.
Myocardial glutathione depletion impairs recovery after short periods of
ischaemia. Circulation 1989; 80: 1449-1457.
246. Werns SW, Lucchesi RB. Free radicals and ischaemic tissue injury. Trends in
Pharmacological Sciences 1990; 11: 161-167.
247. Chautham JC, Seymore AMI, Harmsem E, Radda GK. Depletion of myocardial
glutathione: Its effects on heart function and metabolism during ischaemia and
reperfusion. Cardiovascular Research 1988; 22: 833-839.
248. Singh A, Lee KL, Lee CV, Gold farb RD, Tsan MF. Relation between
myocardial glutathione content and extent of ischaemia reperfusion injury.
Circulation 1989; 1795-1804.
249. Lec, Van Der Valk E, Van Der Laarse A. Buthionine sulfoxamine reduces the
protective capacity of myocytes to withstand peroxide derived free radical
attack. Journal of Molecular and Cellular Cardiology 1993; 25: 519-528.
250. Ge K, Xue A, Bai J, Wanng S. Keshan disease-an endemic cardiomyopathy in
China. Virchows Arch (Pathol Anat) 1983; 104: 1-15.
251. Yoshida T, Watanable M, Engleman DT. Transgenic mice overexpressing
glutathione peroxidase are resistant to myocardial ischemia reperfusion injury.
Journal of Molecular and Cellular Cardiology 1996; 28: 1759-1767.
342
252. Yoshida T, Maulik N, Engleman RM. Glutathione peroxidase knowckout mice
are susceptible to myocardial ischemia reperfusion injury. Circulation 1997; 96:
H216-H220.
253. Hoy S, Magnenat JL, Bronson RT. Mice deficient in cellular glutathione
peroxidase develop normally and show no increased sensitivity to hyperoxia.
Journal of Biological Chemistry 1997; 272: 16644-16651.
254. Jaeschke H, Hoy S, Fisher MA, Lawson JA. Glutathione peroxidase – deficient
mice are more susceptible to neutrophil mediated hepatic parenchymal cell
injury during endotoxemia. Importance of an intracellular oxidant stress.
Hepatology 1999; 29: 443-450.
255. Beck MA, Esworhty RS, Hoy S, Chu FF. Glutathione peroxidase protects mice
from viral induced myocarditis. The Federation of American Society for
Experimental Biology Journal 1998; 12: 1143-1149.
256. Nohl H, Jordan W. The metabolic fate of mitochondrial hydrogen peroxide.
European Journal of Biochemistry 1980; 111: 203-210.
257. Gallagher KP, Buda AJ, Pace D, Garren RA, Shlater M. Failure of superoxide
dismutase and catalase to alter infarct size in conscious dogs after 3 hours of
occlusion followed by reperfusion. Circulation 1986; 73: 1065-1076.
258. Maulic G, Maulik N, Bhandri V. Evaluation of antioxidant effectiveness of few
herbal plants. Free Radical Research 1997; 27: 221-228.
259. Das DK, Maulik N, Moraru I. Gene expression in acute myocardial stress.
Induction by hypoxia, ischemial reperfusion, hyperthermia and oxidative stress.
Journal of Molecular and Cellular Cardiology 1995; 27: 181-193.
260. Silveski-Illiskovic N, Hill M, Chow DA, Single PK. Probucol protects against
adiramycin cardiomyopathy without interfering with its anti tumor effect.
Circulaiton 1995; 91: 10-15.
343
261. Pathania V, Syal N, Hundal MH, Khanduja KL. Geriforte stimulates antioxidant
defense system. Indian Journal of Experimental Biology 1998; 36: 414-417.
262. Tosaki AK, Maulik N, Elliott GT, Blasig IE, Engelman RM, Das DK.
Preconditioning of rat heart with monophosphoryl lipid A: A role of nitric oxide.
Journal of Pharmacology and Experimental Therapeutics 1998; 285: 1274-1279.
263. Rajak S, Banerjee SK, Sood S, Dinda AK, Gupta YK, Gupta SK, Maulik SK.
Emblica officinalis causes myocardial adaptation and profects against oxidative
stress in ischemic-reperfusion injury. Phytotherapy research 2004; 18(1): 54-60.
264. Banerjee SK, Dinda AK, Manchandra SC, Maulik SK. Chronic garlik
administration protects rat heart against oxidative stress induced by ischemic-
reperfusion injury. Biomedcentral Pharmacology 2002; 2: 16.
265. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. Effect of bioactive
tannoid principles of Embelica officinalis on ischemic reperfusion induced
oxidative stress in rat heart. Phytomedicine 2002; 9 (2): 171-174.
266. Narang D, Sood S, Thomas MK, Dinda AK, Maulik SK. Effect of dietary
palmolein oil on oxidative stress associated with ischemic-reperfusion injury in
isolated rat heart. Biomedcentral Pharmacology 2004; 4: 29.
267. Krishnan P, Sharma A, Singh M. Effect of angiotension converting enzyme
inhibitors on ischemic reperfusion induced renal injury in rats. Pharmacological
Research 1998; 37: 23-29.
268. Cavanagh EM, Fraga CG, Ferdes L, Inserra F. Enalapril and captopril enhance
antioxidant defenses in mouse tissues. American Journal of Physiology 1997;
272: R514-R518.
269. Jamayo R. Is cirrhosis of the liver experimentally produced CCl4, an adequate
model of human cirrhosis? Hepatology 1983; 3: 112-120.
344
270. Recknagel RO. CCl4 hepatotoxicity. Pharmacological Review 1967; 19: 145-
208.
271. Recknagel RO. A new direction in the study of carbon tetrachloride
hepatotoxicity. Life sciences 1983; 33: 401-408.
272. Zimmerman HJ and Seef LB. Enzymes in hepatic disease. In: Diagnostic
Enzymology. Edited by Goodly. Lea and Febiger, Philadelphia. 1970; pp 149-
252.
273. Max H, Zhao YC, Yin L, Han DW, Jic X. Studies on the effect of oleanolic acid
on experimental liver injury. Acta Pharmaceutica Sinica 1982; 17: 93-97.
274. Liu J, Liu YP, Mao Q, Klaassen CD. The protective effect of ten triterpenoid
compounds on experimental liver injury in mice. Fundamental and Applied
Toxicology 1994; 22: 34-40.
275. Liu J, Liu YP, Klassen CD. The effect of oleanolic acid on chemical induced
liver injury in mice. Acta Pharmacologica Sinica 1995; 15: 16-23.
276. Liu J. Pharmacology of oleanolic acid and ursolic acid. Journal of
Ethnopharmacology 1995; 49: 57-68.
277. Yabuchi T, Tanika T, Sasatsuka T, yamahara J, Fujimura H. Extraction of
oleanolic acid from sugar beats for the treatment of liver failure. Chemical
Abstracts 1988; 108: 82082.
278. Zhang LZ and Lix F. Study on the mechanism of oleanolic acid against
experimental liver injury in rats. Traditional Medicine and Clinical
Pharmacology 1992; 8: 24-26.
279. Liu J, Liu YP, Madhu C, Klaasen CD. Protective effects of oleanolic acid on
acetaminophen hepatotoxicity in mice. Journal of Pharmacology and
Experimental Therapeutics 1993; 266: 1607-1613.
345
280. Han DW, Max H, Zhao YC, Yin L. The protective effects of oleanolic acid on
experimental cirrhosis. Journal of Traditional Chinese Medicine 1981; 3: 217-
223.
281. Castro JA,, Ferrya GC, Casro CR, Sasame H, Fenos OM, Gillette JR. Prevention
of carbon tetrachloride induced necrosis by inhibition of drug metabolism.
Further studies on the metabolism of their action. Biochemical Pharmacology
1974; 23: 295-302.
282. Yasuda H, Izugami N, Shimadar O, Koba Yakawa Y, Nakanishi M. The
protective effect of Tinoride against CCl4 hepato toxicity. Toxicology and
Applied Pharmacology 1980; 52: 4207-4213.
283. Stajner D, Milic N, Mimica-Dukic N, Lazic B, Igic R. Antioxidant abilities of
cultivated and wild species of garlic. Phytotherapy Research 1998; 12: 513-514.
284. Sanchez-Moreno C, Larrauri JA, Saura-Calixto F. Free radical scavenging
capacity an inhibition of lipid peroxidation of wines, grape juices and related
polyphenolic constituents. Food Research International 1999; 32: 407-412.
285. Gulcin I, Oktay M, Kufrevioglu I, Aslan A. Determination of antioxidant activity
of lichen Centraria islandica (L) Ach. Journal of Ethnopharmacology 2002; 79:
325-329.
286. Leme JG, Hamamura L, Leite MP, Silva MR. Pharmacological analysis of the
acute inflammatory process induced in the rats paw by local injection of
carrageenan and by heating. British Journal of Pharmacology 1973; 48: 88-96.
287. Vinegar R, Schriber W and Hugo R. Biphasic development of carrageenan
edema in rats. Journal of Pharmacology and Experimental Therapeutics 1969;
166: 96-103.
288. Crunkhon P, Meacock SER. Mediators of the inflammation induced in the rat
paw by carrageenan. British Journal of Pharmacology 1971; 42: 392-402.
346
289. Van Arman CG, Begany AJ, Miller LM and Pless HH. Some details of the
inflammations caused by yeast and carrageenan. Journal of Pharmacolgy and
Experimental Thearpeutics 1965; 150: 328-334.
290. Di Rosa M, Sorrentino L. The mechanism of the inflammatory effect of
carrageenan. European Journal of Pharmacology 1968; 4: 340-342.
291. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation
and immunity. Arthritis and Rheumatism 1998; 41: 1141-1151.
292. Moncada S, Palmer RMJ, Higgs EA. Nitric Oxide physiology, pathology and
pharmacology. Pharmacological Reviews 1991; 43: 109-142.
293. Grisham MB, Heuil JD, Wink DA. Nitric Oxide I. Physiological chemistry of
nitric oxide and its metabolites: Implications in inflammation. American Journal
of Physiology 1999; 276: 315-321.
294. Selvemini D, Wang ZQ, Wyatt PS, Bourden DM, Marino MH, Manning PT,
Currie MG. Nitric oxide: A key mediator in the early and late phase of
carrageenan-induced rat paw inflammation. British Journal of Pharmacology
1996; 118(4): 829-838.
295. Mittal CK, Mittal R, Galiotos JK. Nitric Oxide: Regulation and Clinical
Relavance. In: Trends in Clinical Biochemistry and Laboratory Medicine,
Association of Clinical Biochemists of India Publications, 2003: pp 577-580.
296. Gil MI, Tomas-Barberan FA, Hess-Dierce B, Holcroft DM and Kader AA.
Antioxidant activity of pomegranate juice and its relationship with phenolic
composition and processing. Journal of Agricultural and Food Chemistry 2000;
48: 4581-4589.
297. Cano A, Hern andez – Ruiz J, Garcia canovas F, Acosta M and Arnao MB. An
end point method for estimation of the total antioxidant activity in plant material.
Phytochemical analysis 1998; 9: 196-202.
347
298. Nguyen T, Brunson D, Crepsi CL , Penman BW, Wishnok JS, Tannenbaum SR.
DNA damage and mutation in human cells exposed to nitric oxide in-vitro.
Proceedings of National Academy of Sciences USA 1992; 89: 3030-3034.
299. Corbett JA, MC Daniel ML. Does NO mediate autoimmune destruction of beta
cells? Diabetes 1992; 41: 897-890.
300. Szaboc Thiernermannc. Invited Orion: Role of nitric oxide in hemorrhagic,
traumatic and anaphylactic shock and thermal injury. Shock. 1994; 2: 145-155.
301. Thiemermann C. Nitric oxide and septic shock. General Pharmacology 1997; 29:
159-166.
302. Toutouzas PC, Tousoulis D, Davies GJ. Nitric oxide synthesis in atherosclerosis.
European Heart Journal 1998; 19: 1504-1511.
303. Parkinson JF, Mitrovic B, Merrill JE. The role of nitric oxide in multiple
sclerosis. Journal of Molecular Medicine 1997; 75: 174-186.
304. Ohshima H, Tatemichi M, Sawa T. Chemical basis of inflammation-induced
carcinogenesis. Archieves of Biochemistry and Biophysics 2003; 417: 3-11.
305. Sarkar D, Dutta A, Das M, Sarkar K, Mandlac chatterjee M. Effect of aloe vera
on nitric oxide production by macrophages during inflammation Indian Journal
of Pharmacology 2005; 37(6): 371-375.
306. Rao YK, Fang SH, Tzeng YM. Anti-inflammatory activities of constituents
isolated from Phylanthus polyphyllus. Journal of Ethnopharmacology 2006;
103:181-186.
307. Chopra RN, Nayar SL, Chopra IC. Glossary of Indian Medicinal Plants,
Publications and Informations Directorate, CSIR, New Delhi. 1956; pp 39.
308. Anonymous, The Wealth of India, Raw Materials, Publications and Information
Directorate, CSIR, New Delhi. 1988; 2(B): pp 202.
348
309. Asolkar LV, Kakkar KK, Chakre OJ. Glossary of Indian Medicinal Plants with
Active Principles. (II Supplement), Part 1 (A-K). Publications and Information
Directorate, CSIR, New Delhi. 1992; pp 134-135.
310. Kapoor SK, Prakash L and Zaman A. Chemical constituents of Borreria
hispida (Linn.) K. Schum. Indian Journal of Applied Chemistry 1969; 32(6):
402.
311. Sankara Subramanian S, Nair AGR. Distribution of mannitol and flavonols in
some rubiaceous plants. Phytochemistry 1971; 10: 2125-2127.
312. Purushothaman KK, Kalyani K. Isolation of Isorhamnetin from Borreria hispida
Linn. Journal of Research in Indian Medicine, Yoga and Homeopathy 1979; 14:
131-132.
313. Mukherjee KS, Manna TK, Laha S, Chakraborty CK. Phytochemical
investigation of Borreria articularis (Linn.). Journal of Indian Chemical Society
1993; 70: 609-610.
314. Dhar ML, Dhawan BN, Prasad CR, Rastogi RP, Singh KK and Tandon JS.
Screening of Indian plants for biological activity; Part V. Indian Journal of
Experimental Biology 1974; 12: 512-523.
315. Khan SS, Chaghtai SA, Oommacha M. Medicinal plants of rubiaceae of Bhopal.
An ethnobotanical study. Journal of Scientific Research (Bhobal). 1984; 6(1):
37-39.
316. Tipton J, Barnicki T, Smith ET. Quantitative analysis of herbs by GC-MS as an
undergraduate instrumental analysis laboratory exerscise. The Chemical
Educator 1998; 3(3): 1-12.
317. Schoon N, Amelync KC, Vereecken L, Cockelberghs H, Arijs E. A selected ion
flow tube study of the reaction of H3O+, NO+ and O2+ with some monoterpene
oxidation products. International Journal of Mass Spectrometry 2004; 239: 7-16.
349
318. Yu J, Cocker DR, Griffin RJ, Flagnan RC, Seinfeld JH. Gas Phase ozone
oxidation of monoterpenes; gaseous and particulate products. Journal of
Atmospheric Chemistry 1999; 34: 207-258.
319. Yayli N, Kiran Z, Seymen H, Genc H, Kucuki -Slamoglu M. Characterization of
lipids and fatty acids methyl ester contents in leaves and roots of Crocus
vallicola. Turkish Journal of Chemistry 2001; 25: 391-395.
320. Flanagan VP, Ferretti A. Hydrocarbons and polychlorinated biphenyls from the
unsaponifiable fraction of anyhydrous milk fat. Journal of Lipid Research 1973;
14: 306-311.
321. Flanagan VP, Ferretti A, Schwartz DP, Ruth JM. Characterization of two
steroidal ketones and two isoprenoid alcohols in dairy products. Journal of Lipid
Research. 1975; 16: 97-101.
322. Giner JL, Zhao H, Beach DH, Parish EJ, Jayasimhulu K, Kaneshiro ES.
Comprehensive and definitive structural identities of Pneumocystis carnii
sterols. Journal of Lipid Research 2002; 43: 1114-1124.
323. Friedland SS, Lane GH, Longman RT, Train KE. Mass spectra of sterols.
Analytical Chemistry 1959; 31: 169-173.
324. Eneroth P, Hellstrom K, Rhhage R. Identification and quantification of neutral
fecal steroids by gas-liquid chromatography and mass spectrometry : Studies of
human excretion during two dietary regimens. Journal of Lipid Research 1964;
5: 245-262.
325. Kusano G, Beisler J, Sato Y. Steroidal constituents of Solanum xanthocarpum.
Phytochemistry 1973; 12: 397-401.
326. Cheng SJ, Lin TH, Chen CC. Constituents from the stems of Dendrobium
clavatum var auranticum. Journal of Chinese Medicine 2001; 12(3): 211-218.
350
327. Bruni R, Medici A, Guerrini A, Scalia R, Poli R, Romagnoli C, Muzzoli M,
Sacchelti G. Tocopherol, fatty acids and sterol distributions in wild Ecuadorian
Theobroma subincanum (Sterculiaceae) seeds. Food Chemistry 2002; 77: 337-
341.
328. Budzikiewicz H, Wilson JM, Djerassi C. Mass spectrometry in structural and
stereochemical problems XXXII. Pentacyclic triterpenes. Journal of American
Chemical Society 1963; 85: 3688-3699.
329. Loux JJ, De Palma PD, Yankell SL. Antipyretic testing of aspirin in rats.
Toxicology and Applied Pharmacology 1972; 22: 672-675.
330. Kulkarni SK. Pharmacology of Local anaesthetics. In: Hand book of
Experimental Pharmacology, 3rd Edition, Vallabha Prakashan publications, New
Delhi. 1999; pp 150-153.
331. Karamenderes C, Apaydin S. Antispasmodic effect of Achillea nobilis L. subsp,
sipylea (O. Schwarz) Bassler on the rat isolated duodenum. Journal of
Ethanopharmacology 2003; 84: 175-179.
332. Gillespie SH. Medical Microbilogy – Illustrated. Butter Worth Heinemann Ltd.,
U.K. 1994; pp 234-245.
333. Bagchi GD, Singh A, Khanuja SPS, Bansal RP, Singh SC, Kumar S. Wide
spectrum antibacterial and antifungal activities in the seeds of some coprophilous
plants of north Indian plains. Journal of Ethnopharmacology 1999; 64: 69-77.
334. Gan K.H, Lin C.N. Studies on the constituents of Formosan gentianaceous plants
XI. Constituents of Gentiana flam-maculata and Tripterospermum taiwanase
and the anti-hepatotoxic activity of ursolic acid derivatives. Chinese
Pharmaceutical Journal 1988; 40: 77-84.
351
335. Max H, Zhao Y.C, Yin L, Han DW and Wang M.S. Studies on the preventive
and therapeutic effects of ursolic acid on acute hepatic injury in rats. Acta
Pharmaceutica Sinica 1986; 21: 332-335.
336. Shukla B, Viser S, Patnaik GK, Tripathisc, Srimal R.C, Day S, Dobhal P.C.
Hepatoprotective activity in the rat of ursolic acid isolated from Eucalyptus
hybrid. Phytotherapy research 1992; 6: 74-79.
337. Gupta MB, Bhalla TN, Gupta GP, Mitra CR, Bhargava K.P. Anti-inflammatory
activity of natural products (I) - Triterpenoids. European Journal of
Pharmacology 1969; 6: 67-70.
338. Hirota M, Mori T, Yoshio M, Iriye R. Suppression of tumor promoter – induced
inflammation of mouse ear by ursolic acid and 4, 4-dimethylcholestane
derivates. Agricultural and Biological Chemistry 1990; 54: 1073-1075.
339. Singh GB, Singh S, Bani S, Gupta BD, Banerjee S.K. Anti-inflammatory activity
of oleanolic acid in rats and mice. Journal of Pharmacy and Pharmacology 1992;
44: 456-458.
340. Dai Y, Hang B.Q, Lip Z, Tan L.W. Effects of oleanolic acid on immune system
and type I allergic reaction. Acta Pharmacological Sinica 1989; 10: 381-384.
341. Simon A, Najid A, Chulia AJ, Delage C, Rigaud M. Inhibition of lipoxygenase
activity and HL60 leukemic cell proliferation by ursolic acid isolated from
heather flowers (calluna vulgaris) Biochimica et Biophysica Acta 1992; 1125:
68-72.
342. Najid A, Simon A, Cook J, Chable-Rabinovitch H, Delage C, Chulia AJ and
Rignad M. Characterization of ursolic acid as a lipoxygenase and cyclo
oxygenase inhibitor using macrophages, platelets and differentiated HL60
leukemic cells. Federation of European Biochemical Societies 1992; 299: 213-
217.
352
343. Ying QL, Rinehert A.R, Simon S.R and Cherons J.C. Inhibition of human
leucocyte elastase by ursolic acid. Biochemistry Journal 1991; 277: 521-526.
344. Kapil A, Sharma S. Anti-complement activity of oleanolic acid: An inhibitor of
C-3 convertase of the classical complement pathway. Journal of Pharmacy and
Pharmacology 1994; 46: 922-923.